LIVIVO - Search results -

Search results

Result 1 - 10 of total 13

Search options

Article ; Online: Unmasked Kaposi and sarcoidosis immune reconstitution inflammatory syndrome in a patient with AIDS.

Salto, Jack N / Volkow, Patricia / Herrera-Goepfert, Roberto / López-Garcia, Alicia Ivette / Cortes-Garcia, Beatriz Yessenia / García-Pérez, Francisco Osvaldo / Arroyo-Hernandez, Marisol / Rivera-Rosales, Rosa-Maria

AIDS (London, England)

2024 Volume 38, Issue 6, Page(s) 933–934

MeSH term(s)	Humans ; Acquired Immunodeficiency Syndrome/complications ; Acquired Immunodeficiency Syndrome/drug therapy ; Immune Reconstitution Inflammatory Syndrome/diagnosis ; HIV Infections/complications ; HIV Infections/drug therapy ; AIDS-Related Opportunistic Infections/diagnosis ; Sarcoma, Kaposi/complications ; Sarcoma, Kaposi/diagnosis ; Sarcoidosis/complications ; Sarcoidosis/diagnosis ; Antiretroviral Therapy, Highly Active
Language	English
Publishing date	2024-04-04
Publishing country	England
Document type	Journal Article
ZDB-ID	639076-6
ISSN	1473-5571 ; 0269-9370 ; 1350-2840
ISSN (online)	1473-5571
ISSN	0269-9370 ; 1350-2840
DOI	10.1097/QAD.0000000000003851
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2228: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Detección temprana de cáncer de pulmón en México.

Arroyo-Hernández, Marisol / Zinser-Sierra, Juan W / Vázquez-García, Juan Carlos

Salud publica de Mexico

2019 Volume 61, Issue 3, Page(s) 347–351

Abstract: La detección temprana de cáncer pulmonar (CP) en población de alto riesgo tiene el potencial de diagnosticar la enfermedad en estadios tempranos y facilitar el tratamiento oportuno con el fin de disminuir la tasa de mortalidad. En México, como en otros ... ...

Title translation	Lung-cancer screening program in Mexico.
Abstract	La detección temprana de cáncer pulmonar (CP) en población de alto riesgo tiene el potencial de diagnosticar la enfermedad en estadios tempranos y facilitar el tratamiento oportuno con el fin de disminuir la tasa de mortalidad. En México, como en otros países en vías de desarrollo, además del tabaquismo, la exposición al humo de leña se posiciona como uno de los principales factores de riesgo para desarrollar CP, lo cual no se ha considerado en estudios de tamizaje previamente publicados. Distintas interrogantes surgen en relación con quiénes son las personas que presentan un alto riesgo de desarrollar CP en América Latina, cuál es el costo-beneficio de poner en marcha un programa de detección oportuna de CP en México y cuáles son los obstáculos que los países de la región enfrentan para su implementación.
MeSH term(s)	Aged ; Aged, 80 and over ; Early Detection of Cancer ; Humans ; Lung Neoplasms/diagnosis ; Mexico ; Middle Aged
Language	Spanish
Publishing date	2019-07-05
Publishing country	Mexico
Document type	Journal Article
ZDB-ID	954220-6
ISSN	1606-7916 ; 0036-3634
ISSN (online)	1606-7916
ISSN	0036-3634
DOI	10.21149/10326
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 1309: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Radiation-induced lung injury: current evidence.

Arroyo-Hernández, Marisol / Maldonado, Federico / Lozano-Ruiz, Francisco / Muñoz-Montaño, Wendy / Nuñez-Baez, Mónica / Arrieta, Oscar

BMC pulmonary medicine

2021 Volume 21, Issue 1, Page(s) 9

Abstract: Chemo-radiotherapy and systemic therapies have proven satisfactory outcomes as standard treatments for various thoracic malignancies; however, adverse pulmonary effects, like pneumonitis, can be life-threatening. Pneumonitis is caused by direct cytotoxic ...

Abstract	Chemo-radiotherapy and systemic therapies have proven satisfactory outcomes as standard treatments for various thoracic malignancies; however, adverse pulmonary effects, like pneumonitis, can be life-threatening. Pneumonitis is caused by direct cytotoxic effect, oxidative stress, and immune-mediated injury. Radiotherapy Induced Lung Injury (RILI) encompasses two phases: an early phase known as Radiation Pneumonitis (RP), characterized by acute lung tissue inflammation as a result of exposure to radiation; and a late phase called Radiation Fibrosis (RF), a clinical syndrome that results from chronic pulmonary tissue damage. Currently, diagnoses are made by exclusion using clinical assessment and radiological findings. Pulmonary function tests have constituted a significant step in evaluating lung function status during radiotherapy and useful predictive tools to avoid complications or limit toxicity. Systemic corticosteroids are widely used to treat pneumonitis complications, but its use must be standardized, and consider in the prophylaxis setting given the fatal outcome of this adverse event. This review aims to discuss the clinicopathological features of pneumonitis and provide practical clinical recommendations for prevention, diagnosis, and management.
MeSH term(s)	Humans ; Lung Injury/etiology ; Lung Injury/physiopathology ; Lung Injury/therapy ; Neoplasms/radiotherapy ; Radiation Injuries/etiology ; Radiation Injuries/physiopathology ; Radiation Injuries/therapy ; Radiation Pneumonitis/etiology ; Radiation Pneumonitis/physiopathology ; Radiation Pneumonitis/therapy ; Respiratory Function Tests
Language	English
Publishing date	2021-01-06
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2059871-3
ISSN	1471-2466 ; 1471-2466
ISSN (online)	1471-2466
ISSN	1471-2466
DOI	10.1186/s12890-020-01376-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Impact of Tyrosine Kinase Inhibitors on the Immune Response to SARS-CoV-2 Vaccination in Patients with Non-Small Cell Lung Cancer.

Hernández-Pedro, Norma / Arroyo-Hernández, Marisol / Barrios-Bernal, Pedro / Romero-Nuñez, Eunice / Sosa-Hernandez, Victor A / Ávila-Ríos, Santiago / Maravillas-Montero, José Luis / Pérez-Padilla, Rogelio / de Miguel-Perez, Diego / Rolfo, Christian / Arrieta, Oscar

Vaccines

2023 Volume 11, Issue 10

Abstract: Immune dysregulation and cancer treatment may affect SARS-CoV-2 vaccination protection. Antibody production by B-cells play a vital role in the control and clearance of the SARS-CoV-2 virus. This study prospectively explores B-cell seroconversion ... ...

Abstract	Immune dysregulation and cancer treatment may affect SARS-CoV-2 vaccination protection. Antibody production by B-cells play a vital role in the control and clearance of the SARS-CoV-2 virus. This study prospectively explores B-cell seroconversion following SARS-CoV-2 immunization in healthy individuals and non-small cell lung cancer (NSCLC) patients undergoing oncological treatment. 92 NSCLC patients and 27 healthy individuals' blood samples were collected after receiving any COVID-19 vaccine. Serum and mononuclear cells were isolated, and a serum surrogate virus neutralization test kit evaluated SARS-CoV-2 antibodies. B-cell subpopulations on mononuclear cells were characterized by flow cytometry. Patients were compared based on vaccination specifications and target mutation oncological treatment. A higher percentage of healthy individuals developed more SARS-CoV-2 neutralizing antibodies than NSCLC patients (63% vs. 54.3%;
Language	English
Publishing date	2023-10-19
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2703319-3
ISSN	2076-393X
ISSN	2076-393X
DOI	10.3390/vaccines11101612
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated With Radiotherapy.

Barrón, Feliciano / Sánchez, Roberto / Arroyo-Hernández, Marisol / Blanco, Carolina / Zatarain-Barrón, Zyanya L / Catalán, Rodrigo / Ramos-Ramírez, Maritza / Cardona, Andrés F / Flores-Estrada, Diana / Arrieta, Oscar

Frontiers in oncology

2020 Volume 10, Page(s) 570233

Abstract: Introduction: Immune checkpoint inhibitor-related pneumonitis (ICIP) is a potentially life threatening immune-related adverse event (irAE), especially in non-small cell lung cancer (NSCLC) patients. Currently, the potential for increased irAE in ... ...

Abstract	Introduction: Immune checkpoint inhibitor-related pneumonitis (ICIP) is a potentially life threatening immune-related adverse event (irAE), especially in non-small cell lung cancer (NSCLC) patients. Currently, the potential for increased irAE in patients who receive radiotherapy is scarcely known, although a connection between antitumor immune responses and irAEs has been suggested. In this study, we evaluated the development of ICIP in non-small cell lung cancer patients with prior radiotherapy, treated with immunotherapy in the second-line. Methods: In this retrospective trial, we included patients treated with second-line immunotherapy at the National Cancer Institute in Mexico City from February 2015 to February 2018. Clinical, radiological and treatment variables were evaluated according to the presence of ICIP as defined by the Common Terminology Criteria for Adverse Events (4.0) in patients with or without a previous (≥months) history of radiotherapy. Results: Among 101 NSCLC patients who received treatment with ICIs, 22 patients (21.8%) were diagnosed with ICIP, of which 73% (16/22) had a history of radiotherapy (OR 6.04, 95% CI 2.03-18.0, Conclusion: In this real-world cohort of NSCLC patients treated with ICI, the history of prior radiotherapy was associated with increased risk for ICIP development. Unlike other irAEs, grade ≥ 2 ICIP is an independent prognostic factor for decreased survival in NSCLC patients.
Language	English
Publishing date	2020-09-29
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2649216-7
ISSN	2234-943X
ISSN	2234-943X
DOI	10.3389/fonc.2020.570233
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer.

de Miguel-Perez, Diego / Russo, Alessandro / Gunasekaran, Muthukumar / Buemi, Francesco / Hester, Lisa / Fan, Xiaoxuan / Carter-Cooper, Brandon A / Lapidus, Rena G / Peleg, Ariel / Arroyo-Hernández, Marisol / Cardona, Andres F / Naing, Aung / Hirsch, Fred R / Mack, Philip C / Kaushal, Sunjay / Serrano, Maria Jose / Adamo, Vincenzo / Arrieta, Oscar / Rolfo, Christian

Cancer

2022 Volume 129, Issue 4, Page(s) 521–530

Abstract: Background: Immune-checkpoint inhibitors (ICIs) are an effective therapeutic strategy, improving the survival of patients with lung cancer compared with conventional treatments. However, novel predictive biomarkers are needed to stratify which patients ... ...

Abstract	Background: Immune-checkpoint inhibitors (ICIs) are an effective therapeutic strategy, improving the survival of patients with lung cancer compared with conventional treatments. However, novel predictive biomarkers are needed to stratify which patients derive clinical benefit because the currently used and highly heterogenic histological PD-L1 has shown low accuracy. Liquid biopsy is the analysis of biomarkers in body fluids and represents a minimally invasive tool that can be used to monitor tumor evolution and treatment effects, potentially reducing biases associated with tumor heterogeneity associated with tissue biopsies. In this context, cytokines, such as transforming growth factor-β (TGF-β), can be found free in circulation in the blood and packaged into extracellular vesicles (EVs), which have a specific delivery tropism and can affect in tumor/immune system interaction. TGF-β is an immunosuppressive cytokine that plays a crucial role in tumor immune escape, treatment resistance, and metastasis. Thus, we aimed to evaluate the predictive value of circulating and EV TGF-β in patients with non-small-cell lung cancer receiving ICIs. Methods: Plasma samples were collected in 33 patients with advanced non-small-cell lung cancer before and during treatment with ICIs. EV were isolated from plasma by serial ultracentrifugation methods and circulating and EV TGF-β expression levels were evaluated by enzyme-linked immunosorbent assay. Results: Baseline high expression of TGF-β in EVs was associated with nonresponse to ICIs as well as shorter progression-free survival and overall survival, outperforming circulating TGF-β levels and tissue PD-L1 as a predictive biomarker. Conclusion: If validated, EV TGF-β could be used to improve patient stratification, increasing the effectiveness of treatment with ICIs and potentially informing combinatory treatments with TGF-β blockade. Plain language summary: Treatment with immune-checkpoint inhibitors (ICIs) has improved the survival of some patients with lung cancer. However, the majority of patients do not benefit from this treatment, making it essential to develop more reliable biomarkers to identify patients most likely to benefit. In this pilot study, the expression of transforming growth factor-β (TGF-β) in blood circulation and in extracellular vesicles was analyzed. The levels of extracellular vesicle TGF-β before treatment were able to determine which patients would benefit from treatment with ICIs and have a longer survival with higher accuracy than circulating TGF-β and tissue PD-L1, which is the currently used biomarker in clinical practice.
MeSH term(s)	Humans ; Carcinoma, Non-Small-Cell Lung/pathology ; Lung Neoplasms/pathology ; Immune Checkpoint Inhibitors/therapeutic use ; B7-H1 Antigen ; Transforming Growth Factor beta ; Pilot Projects ; Immunotherapy/methods ; Biomarkers, Tumor ; Extracellular Vesicles/pathology ; Transforming Growth Factors/therapeutic use
Chemical Substances	Immune Checkpoint Inhibitors ; B7-H1 Antigen ; Transforming Growth Factor beta ; Biomarkers, Tumor ; Transforming Growth Factors (76057-06-2)
Language	English
Publishing date	2022-12-09
Publishing country	United States
Document type	Journal Article
ZDB-ID	1429-1
ISSN	1097-0142 ; 0008-543X ; 1934-662X
ISSN (online)	1097-0142
ISSN	0008-543X ; 1934-662X
DOI	10.1002/cncr.34576
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.146: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: [No title information]

Arroyo-Hernández, Marisol / Alva-López, Luis Felipe / Rendón, Adrián / Barroso-Villafuerte, Francisco Raúl / Báez-Saldaña, Renata / Corona-Cruz, José Francisco / Farfán-Salazar, Georgina / Guerrero-Ixtlahuac, Jorge / Castillo-González, Patricia / Salmon-Demongin, Alfredo / Zaldívar-Crosby, Guillermo / Bolaño-Guerra, Laura M / Zavala-Cruz, Gad Gamed / Sánchez-Gutiérrez, Alejandro / Rendón-Ramírez, Erick Joel / Magdaleno-Maldonado, Gerardo E / Olivares-Torres, Carlos A / López-Saucedo, Raúl Alejandro / Lizardo-Rodríguez, Adolfo E /

Ortiz-Vázquez, Sandra / Vázquez-García, Jorge / Montes-Narváez, Gabriel / Pacheco-Juárez, Mariana / Arrieta-Rodríguez, Oscar G

Salud publica de Mexico

2022 Volume 64, Issue 5, sept-oct, Page(s) 530–538

Abstract: Objetivo: Proporcionar recomendaciones para la detección temprana de pacientes con alto riesgo de desarrollar cáncer de pulmón (CP) en el primer nivel de atención y su referencia oportuna. Material y métodos. Se realizó una búsqueda detallada de la ... ...

Title translation	Guía de Práctica Clínica para el diagnóstico temprano y la referencia oportuna del cáncer de pulmón.
Abstract	Objetivo: Proporcionar recomendaciones para la detección temprana de pacientes con alto riesgo de desarrollar cáncer de pulmón (CP) en el primer nivel de atención y su referencia oportuna. Material y métodos. Se realizó una búsqueda detallada de la evidencia científica disponible para responder las preguntas de investigación clínica y se utilizó el Panel Delphi modificado para lograr un consenso entre expertos. Resultados: Se generaron 14 recomendaciones siguiendo los estándares de una GPC. Conclusión. El CP representa un problema de salud pública en México; por ello, esta guía establece recomendaciones que apoyan la toma de decisiones sobre la detección precoz y la referencia de pacientes con sospecha de CP en el primer nivel de atención.
MeSH term(s)	Early Detection of Cancer ; Humans ; Lung Neoplasms ; Mexico ; Referral and Consultation ; Retrospective Studies
Language	Spanish
Publishing date	2022-08-26
Publishing country	Mexico
Document type	Journal Article
ZDB-ID	954220-6
ISSN	1606-7916 ; 0036-3634
ISSN (online)	1606-7916
ISSN	0036-3634
DOI	10.21149/13919
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 1309: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Clinical practice guidelines for diagnostic and treatment of the chronic heart failure.

Pavía-López, Abel A / Magaña-Serrano, José A / Cigarroa-López, José A / Chávez-Mendoza, Adolfo / Mayorga-Butrón, José L / Araiza-Garaygordobil, Diego / Ivey-Miranda, Juan B / Méndez-Machado, Gustavo F / González-Godínez, Héctor / Aguilera-Mora, Luisa F / Jordán-Ríos, Antonio / Olmos-Domínguez, Luis / Olalde-Román, Marcos J / Miranda-Malpica, Emma M / Vázquez-Ortiz, Zuilma / Rayo-Chávez, Jorge / Mendoza, Alexandra A / Márquez-Murillo, Manlio F / Chávez-Leal, Sergio A /

Gabriel, Amada Álvarez-San / Silva-García, Marissa A / Pacheco-Bouthiller, Alex D / Aldrete-Velazco, Jorge A / Guizar-Sánchez, Carlos A / Gaxiola-López, Efraín / Guerra-López, Arturo / Figueiras-Graillet, Lourdes / Sánchez-Miranda, Gustavo / Mendoza-Zavala, Genaro H / Aceves-García, Moisés / Chávez-Negrete, Adolfo / Arroyo-Hernández, Marisol / Montaño-Velázquez, Bertha B / Romero-Moreno, Luis F / Baquero-Hoyos, María M / Velasco-Hidalgo, Liliana / Rodríguez-Lozano, Ana L / Aguilar-Gómez, Nancy E / Rodríguez-Vega, Mario / Cossío-Aranda, Jorge E

Archivos de cardiologia de Mexico

2024 Volume 94, Issue Supl 1, Page(s) 1–74

Abstract: Chronic heart failure continues to be one of the main causes of impairment in the functioning and quality of life of people who suffer from it, as well as one of the main causes of mortality in our country and around the world. Mexico has a high ... ...

Title translation	Guía mexicana de práctica clínica para el diagnóstico y el tratamiento de la insuficiencia cardiaca.
Abstract	Chronic heart failure continues to be one of the main causes of impairment in the functioning and quality of life of people who suffer from it, as well as one of the main causes of mortality in our country and around the world. Mexico has a high prevalence of risk factors for developing heart failure, such as high blood pressure, diabetes, and obesity, which makes it essential to have an evidence-based document that provides recommendations to health professionals involved in the diagnosis and treatment of these patients. This document establishes the clinical practice guide (CPG) prepared at the initiative of the Mexican Society of Cardiology (SMC) in collaboration with the Iberic American Agency for the Development and Evaluation of Health Technologies, with the purpose of establishing recommendations based on the best available evidence and agreed upon by an interdisciplinary group of experts. This document complies with international quality standards, such as those described by the US Institute of Medicine (IOM), the National Institute of Clinical Excellence (NICE), the Intercollegiate Network for Scottish Guideline Development (SIGN) and the Guidelines International Network (G-I-N). The Guideline Development Group was integrated in a multi-collaborative and interdisciplinary manner with the support of methodologists with experience in systematic literature reviews and the development of CPG. A modified Delphi panel methodology was developed and conducted to achieve an adequate level of consensus in each of the recommendations contained in this CPG. We hope that this document contributes to better clinical decision making and becomes a reference point for clinicians who manage patients with chronic heart failure in all their clinical stages and in this way, we improve the quality of clinical care, improve their quality of life and reducing its complications.
MeSH term(s)	Humans ; Heart Failure/therapy ; Heart Failure/diagnosis ; Chronic Disease ; Mexico
Language	English
Publishing date	2024-04-22
Publishing country	Mexico
Document type	Journal Article ; Practice Guideline
ZDB-ID	2059019-2
ISSN	1665-1731 ; 1665-1731
ISSN (online)	1665-1731
ISSN	1665-1731
DOI	10.24875/ACM.M24000095
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.

Blake-Cerda, Mónika / Lozano-Ruíz, Francisco / Maldonado-Magos, Federico / de la Mata-Moya, Dolores / Díaz-García, Diego / Lara-Mejía, Luis / Zatarain-Barrón, Zyanya Lucia / Cuevas-Góngora, María-Fernanda / Barron-Barron, Feliciano / Corona-Cruz, José Francisco / Cabrera-Miranda, Luis / Arroyo-Hernández, Marisol / Gerson, Raquel / Arrieta, Oscar

Lung cancer (Amsterdam, Netherlands)

2020 Volume 152, Page(s) 119–126

Abstract: Objectives: Stereotactic Ablative Radiotherapy (SABR) has shown high rates of local control and prolonged survival in early-stage non-small cell lung cancer (NSCLC), though its role in oligometastatic disease is undefined. This study aimed to evaluate ... ...

Abstract	Objectives: Stereotactic Ablative Radiotherapy (SABR) has shown high rates of local control and prolonged survival in early-stage non-small cell lung cancer (NSCLC), though its role in oligometastatic disease is undefined. This study aimed to evaluate SABR as a local consolidative therapy (LCT) in oligometastatic NSCLC patients. Methods: In this prospective, single-arm phase 2 trial, we sought to evaluate SABR in patients with stage IV NSCLC, with ≤ five lesions, including the primary tumor. Patients received initial systemic therapy according to international guidelines. Patients without progression after front-line therapy (two months of targeted therapy and ≥ four cycles of chemotherapy) were evaluated by an 18F-FDG-PET/CT to receive consolidative SABR (45-60 Gy in 3-5 fractions) to the primary and all intrapulmonary metastatic sites. The primary endpoint was progression-free survival (PFS); secondary endpoints were overall survival (OS) and toxicity. Results: A total of 47 patients were included. Mean age was 58.9 years, 59.6 % were female, 87.2 % had adenocarcinoma histology, and the contralateral lung was the main site of metastases in 42.6 %. All patients received systemic front-line therapy, chemotherapy in 61.7 %, and a tyrosine kinase inhibitor (TKI) in 38.3 %. Disease control rate (DCR) and complete metabolic response (CMR) to SABR were 93.6 % and 70.2 %. Median PFS was 34.3 months (95 %CI; 31.1-38.8) for the total cohort; patients with a CMR had a median PFS of 53.9 monthsvs.31.9 months in those without CMR (p = 0.011). Median OS was not reached.Grade 1, 2, and 3 pneumonitis were observed in 79.5 % (31/39), 12.8 % (5/39) and 7.7 % (3/39), respectively. No grade ≥4 toxicities were observed. Conclusion: The use of SABR as LCT in oligometastatic NSCLC patients was well tolerated and showed favorable results regarding PFS and OS compared with historical data. The benefit was significantly higher in patients who reached a CMR as assessed by 18F-FDG-PET/CT.
MeSH term(s)	Carcinoma, Non-Small-Cell Lung/radiotherapy ; Carcinoma, Non-Small-Cell Lung/surgery ; Female ; Humans ; Lung Neoplasms/radiotherapy ; Lung Neoplasms/surgery ; Male ; Middle Aged ; Positron Emission Tomography Computed Tomography ; Progression-Free Survival ; Prospective Studies ; Radiosurgery ; Treatment Outcome
Language	English
Publishing date	2020-12-28
Publishing country	Ireland
Document type	Clinical Trial, Phase II ; Journal Article
ZDB-ID	632771-0
ISSN	1872-8332 ; 0169-5002
ISSN (online)	1872-8332
ISSN	0169-5002
DOI	10.1016/j.lungcan.2020.12.029
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2135: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 423: Show issues

Order via subito

Details ▾

Article ; Online: Longitudinal Evaluation of Lung Function in Patients With Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation Therapy.

Torre-Bouscoulet, Luis / Arroyo-Hernández, Marisol / Martínez-Briseño, David / Muñoz-Montaño, Wendy R / Gochicoa-Rangel, Laura / Bacon-Fonseca, Ludwing / Pérez-Padilla, Rogelio / Vergara, Edgar / García-Sancho, Cecilia / Lozano-Ruiz, Francisco / Fernández-Plata, Rosario / Guzmán-Barragán, Abigail / Arrieta, Oscar

International journal of radiation oncology, biology, physics

2018 Volume 101, Issue 4, Page(s) 910–918

Abstract: Purpose: In lung cancer patients, radiation therapy modifies lung architecture, resulting in functional deterioration, which worsens symptoms and reduces quality of life.: Methods and materials: A multicenter, prospective, longitudinal study was ... ...

Abstract	Purpose: In lung cancer patients, radiation therapy modifies lung architecture, resulting in functional deterioration, which worsens symptoms and reduces quality of life. Methods and materials: A multicenter, prospective, longitudinal study was conducted in a cohort of patients with locally advanced and oligometastatic non-small cell lung cancer treated with concurrent chemoradiation therapy (CCRT). A wide array of pulmonary function tests (forced spirometry, body plethysmography, impulse oscillometry, carbon monoxide diffusing capacity, fraction of exhaled nitric oxide, arterial blood gases, and 6-minute walk test) were used to evaluate lung function at baseline; after radiation therapy; and at 6, 12, 24, and 48 weeks after CCRT. Relative changes in test results (percentages) were estimated at the aforementioned intervals and compared with baseline results. Results: Thirty-seven patients completed the follow-up and were included in the analysis. After CCRT, patients showed a maximum decline in lung volumes as follows: (1) 31% in forced expiratory volume in the first second after 24 weeks (P = .008), (2) 9.6% in forced vital capacity after 48 weeks (P = .04), and (3) 15.1% in total lung capacity after 48 weeks (P = .0015). Similarly, at 12 weeks after CCRT, patients showed a 21.8% decrease in carbon monoxide diffusing capacity (P = .002). Increases were found in total airway resistance (respiratory system resistance at 5 Hz), frequency dependence of resistance (change in respiratory system resistance at 5 Hz-respiratory system resistance at 20 Hz, P = .012), and reactance (P = .0003 for respiratory system reactance at 5 Hz and P = .001 for reactance area), which together indicate small-airway dysfunction. Conclusions: The longitudinal evaluation of lung function through pulmonary function tests detects CCRT-induced damage before the appearance of clinical symptoms associated with CCRT lung toxicity.
MeSH term(s)	Aged ; Airway Resistance ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carboplatin/administration & dosage ; Carcinoma, Non-Small-Cell Lung/pathology ; Carcinoma, Non-Small-Cell Lung/physiopathology ; Carcinoma, Non-Small-Cell Lung/therapy ; Chemoradiotherapy/methods ; Female ; Forced Expiratory Volume ; Humans ; Lung/physiopathology ; Lung/radiation effects ; Lung Neoplasms/pathology ; Lung Neoplasms/physiopathology ; Lung Neoplasms/therapy ; Male ; Middle Aged ; Oscillometry ; Paclitaxel/administration & dosage ; Plethysmography, Whole Body ; Prospective Studies ; Respiratory Function Tests ; Vital Capacity ; Walk Test
Chemical Substances	Carboplatin (BG3F62OND5) ; Paclitaxel (P88XT4IS4D)
Language	English
Publishing date	2018-04-12
Publishing country	United States
Document type	Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
ZDB-ID	197614-x
ISSN	1879-355X ; 0360-3016
ISSN (online)	1879-355X
ISSN	0360-3016
DOI	10.1016/j.ijrobp.2018.04.014
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1218: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito